Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295315 | 0.98 | MEN1 (0.47) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL18843239 | 0.87 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL22814733 | 0.86 | MEN1 (0.41) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL14776705 | 0.83 | MEN1 (0.49) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL23985309 | 0.82 | TDP1 (0.46) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL14684133 | 0.82 | DGAT1 (0.47) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL1332098 | 0.82 | DGAT1 (0.47) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL21952156 | 0.82 | TDP1 (0.46) | MEN1GAAKMT2ATDP1CTSS | |
| SCHEMBL5509686 | 0.82 | MAOA (0.47) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL842921 | 0.80 | TDP1 (0.52) | MEN1GAAKMT2ATDP1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| EP-0830136-A1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIVERSITY OF HAWAII (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1998009955-A1 | PROCESS AND NOVEL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| US-5721251-A | INCREASING SECRETION OF GROWTH HORMONE IN HUMANS AND ANIMALS | MERCK & CO., INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5721250-A | ADMINISTERING TO TREAT PHYSIOLOGICAL AND MEDICAL CONDITIONS CHARACTERIZED BY A DEFICIENCY IN GROWTH HORMONE SECRETION: SHORT STATURE | MERCK & CO. INC. (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1996040184-A1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIVERSITY OF HAWAII (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5578593-A | RELEASING GROWTH HORMONES FOR ANIMALS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0739204-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| US-5492920-A | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone | MERCK & CO., INC. (US) | 1996-02-20 | — | — | US | disclosed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1995013069-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | MEN1 3255/4885GAA 2244/4885KMT2A 3288/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | MEN1 3290/4885GAA 2222/4885KMT2A 3363/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885GAA 510/4885KMT2A 2213/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885GAA 510/4885KMT2A 2213/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885GAA 510/4885KMT2A 2213/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885GAA 510/4885KMT2A 2213/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | MEN1 4216/4885GAA 173/4885KMT2A 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.